Derivation and validation of a preoperative prognostic model for resectable pancreatic ductal adenocarcinoma

被引:0
|
作者
Shuai Xu [1 ,2 ]
Xiu-Ping Zhang [1 ]
Guo-Dong Zhao [1 ]
Wen-Bo Zou [1 ]
Zhi-Ming Zhao [1 ]
Qu Liu [1 ]
Ming-Gen Hu [1 ]
Rong Liu [1 ]
机构
[1] Faculty of Hepato-Biliary-Pancreatic Surgery, The First Medical Center, Chinese PLA General Hospital
[2] Department of Liver Transplantation and Hepatobiliary Surgery, Shandong Provincial Hospital Affiliated to Shandong First Medical University
关键词
D O I
暂无
中图分类号
R735.9 [胰腺肿瘤];
学科分类号
摘要
Background: The prognosis of patients with pancreatic ductal adenocarcinoma(PDAC) remains poor even after radical pancreaticoduodenectomy(PD). The study aimed to develop and validate a novel preoperative prognostic model to accurately predict the long-term survival of patients with PDAC.Methods: Patients with PDAC of pancreatic head from Chinese PLA General Hospital were included. The preoperative PDAC model with contour plots was developed using a non-linear model in the training cohort and then tested in the validation cohort.Results: Of 421 patients who met the inclusion criteria, 280 were in the training cohort and 141 in the validation cohort. Contour plots for preoperative PDAC model were established to visually predict the survival probabilities of these patients, based on preoperative carbohydrate antigen 19-9, preoperative fibrinogen to albumin ratio and pain symptoms. This model stratified patients into low-and high-risk groups with distinctly different long-term survival in the training cohort [median overall survival(OS)32.1 vs. 17.5 months; median recurrence-free survival(RFS) 19.3 vs. 10.0 months, both P < 0.001] and the validation cohort(median OS 28.3 vs. 19.0 months; median RFS 17.5 vs. 11.2 months, both P < 0.001).Time-dependent receiver operating characteristic and decision curve analyses revealed that the model provided higher diagnostic accuracy and superior net benefit compared to other staging systems.Conclusions: This study constructed and validated a novel preoperative prognostic model that can accurately and conveniently predict the long-term survival of patients with resectable PDAC of pancreatic head. Besides, the model can screen high-risk patients with poor prognosis, which may provide references for personal treatment strategies in the future.
引用
收藏
页码:160 / 168
页数:9
相关论文
共 50 条
  • [41] Prognostic Value of Preoperative Nutritional and Immunological Factors in Patients with Pancreatic Ductal Adenocarcinoma
    Abe, Toshiya
    Nakata, Kohei
    Kibe, Shin
    Mori, Yasuhisa
    Miyasaka, Yoshihiro
    Ohuchida, Kenoki
    Ohtsuka, Takao
    Oda, Yoshinao
    Nakamura, Masafumi
    ANNALS OF SURGICAL ONCOLOGY, 2018, 25 (13) : 3996 - 4003
  • [42] The prognostic significance of preoperative nutritional status in resected pancreatic ductal adenocarcinoma (PDAC)
    Paiella, S.
    Trestini, I.
    Sperduti, I.
    Sandini, M.
    Elio, G.
    Melisi, D.
    Auriemma, A.
    Solda, C.
    Tregnago, D.
    Avancini, A.
    Secchettin, E.
    Bonamini, D.
    Malleo, G.
    Gianotti, L.
    Pilotto, S.
    Bassi, C.
    Milella, M.
    ANNALS OF ONCOLOGY, 2019, 30 : 726 - 726
  • [43] Optimal Treatment for Octogenarians With Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma
    Satoi, S.
    Yamamoto, T.
    Uchida, K.
    Fujii, T.
    Kin, T.
    Asano, T.
    Hanada, K.
    Itoi, T.
    Murakami, Y.
    Igarashi, H.
    Eguchi, H.
    Kuroki, T.
    Shimizu, Y.
    Tani, M.
    Tanno, S.
    Tsuji, Y.
    Hirooka, Y.
    Masamune, A.
    Mizumoto, K.
    Shimokawa, T.
    Yamaue, H.
    Okazaki, K.
    PANCREAS, 2019, 48 (10) : 1516 - 1517
  • [44] Prognostic Impact of the Preoperative Systemic Inflammation Score in Patients With Pancreatic Ductal Adenocarcinoma
    Iguchi, Tomohiro
    Iseda, Norifumi
    Hirose, Kosuke
    Itoh, Shinji
    Harada, Noboru
    Ninomiya, Mizuki
    Sugimachi, Keishi
    Honboh, Takuya
    Maeda, Takashi
    Sadanaga, Noriaki
    Matsuura, Hiroshi
    AMERICAN SURGEON, 2023, 89 (06) : 2213 - 2219
  • [45] Prognostic Value of Preoperative Nutritional and Immunological Factors in Patients with Pancreatic Ductal Adenocarcinoma
    Toshiya Abe
    Kohei Nakata
    Shin Kibe
    Yasuhisa Mori
    Yoshihiro Miyasaka
    Kenoki Ohuchida
    Takao Ohtsuka
    Yoshinao Oda
    Masafumi Nakamura
    Annals of Surgical Oncology, 2018, 25 : 3996 - 4003
  • [46] Identification and validation of heterotypic cell-in-cell structure as an adverse prognostic predictor for young patients of resectable pancreatic ductal adenocarcinoma
    Huang, Hongyan
    He, Meifang
    Zhang, Yanbin
    Zhang, Bo
    Niu, Zubiao
    Zheng, You
    Li, Wen
    Cui, Peilin
    Wang, Xiaoning
    Sun, Qiang
    SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2020, 5 (01)
  • [47] Identification and validation of heterotypic cell-in-cell structure as an adverse prognostic predictor for young patients of resectable pancreatic ductal adenocarcinoma
    Hongyan Huang
    Meifang He
    Yanbin Zhang
    Bo Zhang
    Zubiao Niu
    You Zheng
    Wen Li
    Peilin Cui
    Xiaoning Wang
    Qiang Sun
    Signal Transduction and Targeted Therapy, 5
  • [48] Adjuvant Treatment of Surgically Resectable Pancreatic Ductal Adenocarcinoma
    Tesfaye, Anteneh A.
    Philip, Philip A.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (01) : 54 - 63
  • [49] Neoadjuvant Treatment for Borderline Resectable Pancreatic Ductal Adenocarcinoma
    Kaufmann, Benedikt
    Hartmann, Daniel
    D'Haese, Jan G.
    Stupakov, Pavel
    Radenkovic, Dejan
    Gloor, Beat
    Friess, Helmut
    DIGESTIVE SURGERY, 2019, 36 (06) : 455 - 461
  • [50] Contemporary Review of Borderline Resectable Pancreatic Ductal Adenocarcinoma
    Bonds, Morgan
    Rocha, Flavio G.
    JOURNAL OF CLINICAL MEDICINE, 2019, 8 (08)